Principal Investigator
Justin Watts
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20240437
Clinical Trial Summary
A Phase 1/1b Open-Label, Dose Escalation, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) or Higher-Risk Myelodysplastic Syndrome (HR-MDS)
Phase
Phase I
Funding Agency/Sponsor
Industrial
Disease
Leukemia/heme
Contact Information
Phone Number
305-243-2647